All eyes on data on Biogen’s tau therapy

Biogen’s experimental anti-tau therapy, diranersen, demonstrated slowed cognitive decline in early Alzheimer’s patients during Phase 2 trials, according to data presented at the Alzheimer’s Association International Conference (AAIC). The results—comparable to approved amyloid-targeting drugs—mark a potential shift toward tau-focused treatments, a long-elusive target in dementia research. Coverage from *Fierce Biotech*, *STAT*, and *AP News* highlights the drug’s Phase 2 outcomes, emphasizing its ability to reduce tau protein accumulation while achieving clinical benefits.

Biogen’s own statement underscores “meaningful clinical outcomes” and “robust tau reduction,” framing the findings as a milestone in addressing unmet needs for early-stage Alzheimer’s patients. The data has reignited discussions about tau’s role in disease progression, though no Phase 3 results have yet been disclosed. Next steps hinge on Biogen’s plans for Phase 3 trials and regulatory engagement.

If confirmed in later stages, the therapy could challenge the dominance of amyloid-beta treatments.